Research Article

Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment

Volume: 9 Number: 3 September 30, 2018
EN TR

Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment

Abstract

Aim: Beside efficacy of the shock wave lithotripsy (SWL) procedure, also its negative effects on the kidneys, its relation with the oxidant/antioxidant balance and the search after biomarkers for the detection of this negative effect gained interest in the recent years. The aim of the study is to investigate the possible usage of  total antioxidant status (TAS), total oxidant status (TOS), oxidative stress index (OSI), Paraoxonase-1    (PON-1) and Interleukin 6 (IL-6) parameters as biomarkers for renal injury/trauma  in the early period by patients undergoing SWL due to kidney stones.

Material and Methods: Forty patients receiving SWL therapy due to kidney stones were included to study by collecting their blood samples before and 2 hours after the procedure.

Results: It was observed that SWL therapy has deteriorated the oxidant/antioxidant balance in terms of the oxidants by analyzing the increase of IL-6 (P <0,01) and decrease in PON-1 (P = 0.049). There was no change observed in TAS (P = 0.178) and TOS (P = 0.175) and OSI (P = 0.551) parameters.

Conclusion: This has shown that IL-6 and PON-1 may be more sensitive markers of renal injury after SWL in early period.

Keywords

References

  1. 1. Silay MS, Ellison JS, Tailly T, Caione P. Update on Urinary Stones in Children: Current and Future Concepts in Surgical Treatment and Shockwave Lithotripsy. Eur Urol Focus. 2017; 9: 2405-4569.
  2. 2. Rajiv G, Deepak D, Naval K et al. Does the type of steinstrasse predict the outcome of expectant therapy? Indian J Urol 2006; 22: 135.
  3. 3. Platonov MA, Gillis AM, Kavanagh KM. Pacemakers, implantable cardioverter/defibrillators, and extracorporeal shockwave lithotripsy: evidence-based guidelines for the modern era. J Endourol 2008; 22: 243.
  4. 4. Aksoy H, Aksoy Y, Turhan H, Keleş S, Ziypak T, Ozbey I. The effect of shock wave lithotripsy on nitric oxide and malondialdehyde levels in plasma and urine samples. Cell Biochem Funct 2007; 25: 533–36.
  5. 5. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004; 286: 431-44.
  6. 6. Dundar M, Kocak I, Yenisey C, Serter M, Ozeren B. Urinary and serum cytokine levels in patients undergoing SWL. BJU 2001; 27: 495–99.
  7. 7. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007; 2: 22-30.
  8. 8. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochemical Pharmacology 2011; 81: 337-44.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

September 30, 2018

Submission Date

June 11, 2018

Acceptance Date

June 11, 2018

Published in Issue

Year 2018 Volume: 9 Number: 3

APA
Yuvanc, E., Tuglu, D., Gur, S., Ozan, T., Kısa, Ü., Batislam, E., & Yılmaz, E. (2018). Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. Turkish Journal of Clinics and Laboratory, 9(3), 173-178. https://doi.org/10.18663/tjcl.432886
AMA
1.Yuvanc E, Tuglu D, Gur S, et al. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. 2018;9(3):173-178. doi:10.18663/tjcl.432886
Chicago
Yuvanc, Ercan, Devrim Tuglu, Serhan Gur, et al. 2018. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory 9 (3): 173-78. https://doi.org/10.18663/tjcl.432886.
EndNote
Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E (September 1, 2018) Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. Turkish Journal of Clinics and Laboratory 9 3 173–178.
IEEE
[1]E. Yuvanc et al., “Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment”, TJCL, vol. 9, no. 3, pp. 173–178, Sept. 2018, doi: 10.18663/tjcl.432886.
ISNAD
Yuvanc, Ercan - Tuglu, Devrim - Gur, Serhan - Ozan, Tunc - Kısa, Üçler - Batislam, Ertan - Yılmaz, Erdal. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory 9/3 (September 1, 2018): 173-178. https://doi.org/10.18663/tjcl.432886.
JAMA
1.Yuvanc E, Tuglu D, Gur S, Ozan T, Kısa Ü, Batislam E, Yılmaz E. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. 2018;9:173–178.
MLA
Yuvanc, Ercan, et al. “Clinical Use of Specific Markers TAS, TOS, PON and IL-6 by the Evaluation of Kidney Damage in Patients Receiving SWL Treatment”. Turkish Journal of Clinics and Laboratory, vol. 9, no. 3, Sept. 2018, pp. 173-8, doi:10.18663/tjcl.432886.
Vancouver
1.Ercan Yuvanc, Devrim Tuglu, Serhan Gur, Tunc Ozan, Üçler Kısa, Ertan Batislam, Erdal Yılmaz. Clinical use of specific markers TAS, TOS, PON and IL-6 by the evaluation of kidney damage in patients receiving SWL treatment. TJCL. 2018 Sep. 1;9(3):173-8. doi:10.18663/tjcl.432886